Navigation Links
Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
Date:2/6/2013

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTC BB: CTVN) a biopharmaceutical company that develops innovative alpha particle immunotherapeutics, is pleased to announce that Mr. Jack Talley , Actinium's President & CEO will be presenting at the 15th Annual BIO CEO & Investor Conference on Monday, February 11th at 10:15 AM EST.  Mr. Talley will provide an overview of the Company and its corporate activities. The logistics and webcast information are shown below.

Details Of The Event

Date: February 11, 2013

Time: 10:15 AM EST

Location: Park South, 4th Floor; Waldorf Astoria Hotel; New York, NY

Live and Archived Webcast link:

http://www.veracast.com/webcasts/bio/ceoinvestor2013/97107391.cfm

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:
Visit our web site www.actiniumpharmaceuticals.com or contact:

Media: 
Dennis S. Dobson Jr., 203-258-0159

Jack Talley , CEO 
Actinium Pharmaceuticals Inc. 

Tel:  (646) 459-4201 

E-mail: actimaba@actiniumpharmaceuticals.com

Investors: 

Jeff Ramson  
CEO of ProActive Capital Group, LLC 

Tel:  (646) 863-6341 

E-mail: jramson@proactivecapitalgroup.com
www.proactivecapitalgroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
2. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
3. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
4. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
5. Actinium Pharmaceuticals Announces New Round of Financing
6. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
7. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
8. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
9. Actinium Pharmaceuticals Strengthens Management Team
10. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
11. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017 ... Summary GlobalData,s new report, "South Korea Insulin Delivery ... the South Korea Insulin Delivery market. The report provides ... and average prices (USD) within market segments - Insulin ... Accessories. The report also provides company shares and ...
(Date:1/18/2017)... Philadelphia Pediatric Medical Device Consortium (PPDC) has announced seed grants ... Consortium chose those companies from eight finalists in a ... The devices under development are a powered orthotic arm brace ... system for emergency situations and a device that gradually corrects ... ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 ... by Product Type and by Application: Global Opportunity Analysis and Industry Forecast, 2014 ... and is expected to reach $1,127 million by 2022, growing at a CAGR ... with two-fifths share, in terms of revenue. Continue ... ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 2017 , ... Bio-Optronics Inc. is proud to announce the ... to seamlessly integrate and streamline the way researchers prepare and conduct patient visits. ... and improving efficiency significantly for users – a first in the CTMS industry. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate ... in 2017 who are passionate about making a difference in the lives of ... in Tampa, UMA, a nonprofit healthcare educational institution, has more than 30,000 alumni ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the third year running, ... and the surrounding area, is inaugurating a charity event to help raise ... as Lou Gehrig's disease or motor neurone disease, is a deadly neurological disorder ...
(Date:1/19/2017)... CA (PRWEB) , ... January 18, 2017 , ... The ... while driving during a rain storm by slowing down and increasing the space between ... Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes that, rain ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... designs that will simplify the editing process for all media productions," said Christina ... a package of 30 simplistically styled self-animating paragraphs designed for multi-lined text purposes. ...
Breaking Medicine News(10 mins):